Recruiting Prostate Cancer Studies in Albany
Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen
The purpose of this study is to assess the impact of ibuprofen in men with elevated serum PSA....
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and elevated prostate-speci...
About Prostate Cancer Clinical Trials in Albany
Prostate cancer develops in the prostate gland and is one of the most common cancers in men. Many prostate cancers grow slowly, but some can be aggressive. Treatment options range from active surveillance to surgery, radiation, and hormone therapy.
There are currently 2 prostate cancer clinical trials recruiting participants in Albany, NEW%20YORK. These studies are seeking a combined 398 participants. Research is being sponsored by University of Chicago, Albany Medical College. Clinical trial participation is free and participants receive study-related medical care at no cost.
Prostate Cancer Clinical Trials in Albany — FAQ
Are there prostate cancer clinical trials in Albany?
Yes, there are 2 prostate cancer clinical trials currently recruiting in Albany, NEW%20YORK. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Albany?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Albany research site will contact you about next steps.
Are clinical trials in Albany free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Albany studies also compensate for your time and travel.
What prostate cancer treatments are being tested?
The 2 active trials in Albany are testing new therapies including novel drugs, biologics, and treatment approaches for prostate cancer.
Data updated March 2, 2026 from ClinicalTrials.gov